Adjuvant chemotherapy-associated lipid changes in breast cancer patients
Authors:
Open Access
- 14 August 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (33) , e21498
Abstract
Adjuvant chemotherapy may cause alterations in serum lipids in postoperative breast cancer (BC) patients, but the specific alterations caused by different chemotherapy regimens remain unclear. The aim of this study was to investigate the status of serum lipids pre- and post-chemotherapy and to compare the side effects of different chemotherapy regimens on serum lipid. We retrospectively analysed the lipid profiles of 1934 consecutive postoperative BC patients who received one of the following chemotherapy regimens: The levels of triglycerides (TG), total cholesterols (TC), and low-density lipoprotein (LDL-C) were significantly elevated in patients who received chemotherapy regimens above (P < .001). With respect to different chemotherapy regimens, FEC had less side effects on lipid profiles (TG (P = .006), high-density lipoprotein (HDL-C) (P < .001), and LDL-C (P < .001)) than TC regimen and AC-T and EC-T regimen. Also, the incidence of newly diagnosed dyslipidemia after chemotherapy was lower in FEC group than TC group and AC-T and EC-T group (P < .001). Additionally, the magnitude of the alterations in lipid profiles (TG, TC, HDL-C, and LDL-C) was greater in premenopausal patients than that of the postmenopausal patients (P = .004; P < .001; P = .002; P = .003, respectively). Moreover, after adjusting for multiple baseline covariates, anthracycline-plus-taxane-based regimens (AC-T and EC-T) were still statistically associated with a high level of TG (P = .004) and a low level of HDL-C (P = .033) after chemotherapy compared with FEC regimen. Also, body mass index (BMI) > 24 was associated with abnormal lipid profiles (TG, TC, HDL-C, LDL-C) post-chemotherapy compared with BMI ≤ 24 (P < .001; P = .036; P = .012; P = .048, respectively). BC patients receiving chemotherapy may have elevated lipid profiles, and anthracycline-based regimen had less side effects on lipid profiles compared with regimens containing taxane. Therefore, it is necessary to take lipid metabolism into consideration when making chemotherapy decisions and dyslipidemia prevention and corresponding interventions are indispensable during the whole chemotherapy period.Keywords
Funding Information
- National Natural Science Foundation of China (No.31900970)
- Sichuan Science and Technology Program (No. 2019YFS0338)
This publication has 49 references indexed in Scilit:
- Body weight changes in breast cancer patients following adjuvant chemotherapy and contributing factorsMolecular and Clinical Oncology, 2013
- Assessing Non–Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity PrevalenceAmerican Journal of Epidemiology, 2013
- Anthracycline Causes Impaired Vascular Endothelial Function and Aortic Stiffness in Long Term Survivors of Childhood CancerPathology and Oncology Research, 2012
- Impact of comorbidity on management and mortality in women diagnosed with breast cancerBreast Cancer Research and Treatment, 2012
- Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapyBritish Journal of Nutrition, 2012
- Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort studyBreast Cancer Research, 2011
- Association between ESR2 Genetic Variants and Risk of Myocardial InfarctionClinical Chemistry, 2008
- Competing Causes of Death for Women With Breast Cancer and Change Over Time From 1975 to 2003American Journal of Clinical Oncology, 2008
- Reciprocal Relationships Between Insulin Resistance and Endothelial DysfunctionCirculation, 2006
- Changes in Body Fat and Weight After a Breast Cancer Diagnosis: Influence of Demographic, Prognostic, and Lifestyle FactorsJournal of Clinical Oncology, 2005